Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
This study will rigorously evaluate the clinical and cost effectiveness and potential for “real-world” implementation of an innovative intervention that integrates a behavioral weight loss program and a collaborative stepped care program for depression, incorporates conventional clinic- and home-based modes of care delivery (e.g., office visits plus phone consults and take-home DVD), and leverages low-cost, wide-reach health information technologies (e.g., Web, secure email, and mobile texting).
Given its focus on transforming primary care management of obesity and depression and common cardiometabolic risk factors to evidence-based, patient-centered care, as well as the likely scalability of the proposed intervention, the study has high potential for significant clinical and public health impact.
Subaward PIs are:
- Wayne Katon, MD, University of Washington;
- Kaye Kramer, DrPH, University of Pittsburgh;
- Veronica Yank, MD, Stanford University of Medicine.
- Jeremy Goldhaber-Fiebert, PhD, Stanford University School of Medicine
- Mark Snowden, MD, University of Washington.
- Megan Lewis, PhD, RTI International, is Consulting Co-Investigator
- Philip Lavori, PhD, serves as Consultant.
PAMF physician advisers are:
- Bahar Aghighi, M.D., FACE, Endocrinology, Diabetes & Metabolism
- Meg Durbin, M.D., Regional Vice President, Care Coordination, Peninsula Coastal Region, Sutter Health
- Edward Yu, M.D., Family Medicine, Medical Director for Quality
Lenard Lesser, M.D., MSHS, serves as consulting investigator.
National Heart, Lung, and Blood Institute
Investigator: Alice R. Pressman, Ph.D., M.S.